In vivo experiments have shown that downregulation of AKR1B10 promotes tumor growth and increases FGF1 expression, suggesting that AKR1B10 may play a tumor-suppressive role in CRC by decreasing the level of FGF1 (3). This evidence concerns the gene AKR1B10 and colorectal carcinoma.